Q (sonnet): what do idh1 mutations do?

═ answer (success)
IDH1 (isocitrate dehydrogenase 1) mutations are recurrent hotspot alterations found across several cancer types in cBioPortal, most notably gliomas, acute myeloid leukemia (AML), and cholangiocarcinoma (intrahepatic bile duct cancer).

A brief, general (non-cBioPortal) explanation of the biology: IDH1 normally encodes a metabolic enzyme that converts isocitrate to α-ketoglutarate in the cytoplasm. The recurrent mutations seen in cancer (most commonly at codon R132, e.g., R132H) are gain-of-function changes that cause the mutant enzyme to instead produce an abnormal metabolite, 2-hydroxyglutarate (2-HG). 2-HG accumulation is thought to interfere with enzymes that regulate DNA and histone methylation, altering gene expression and cell differentiation — this is a widely cited mechanism in the research literature, not something I pulled from the cBioPortal database itself.

Note: I have not queried cBioPortal for driver/oncogenicity annotations, so I can't state from the database which specific IDH1 variants are flagged as oncogenic drivers — that would require checking OncoKB-style annotations for a specific study.

Would you like me to:
- Pull mutation frequency and specific variant breakdown (e.g., R132H vs. R132C) for IDH1 in a particular study (e.g., glioma, AML, cholangiocarcinoma)?
- Show IDH1 mutation distribution across cancer types?
- Open the cBioPortal Mutations view for IDH1 in a specific cohort?

Let me know which cohort/context you're interested in and I can generate the exact data and a direct link.